Biasca, Switzerland, November 27, 2017 – On Friday November 24,2017, 10 students received the Helsinn Advanced Synthesis 2017/2018 Education Scholarship from Fabio Regazzi, National Councillor, Biasca’s Mayor, Loris Galbusera, Omar Terraneo, Member of the Biasca Council, Waldo Mossi, Local General Manager, Helsinn Advanced Synthesis, Biasca and Paolo Guainazzi, Member of the Board.
The educational scholarships of 5.000.-CHF each, for a total of 50.000 CHF, sponsored by Helsinn Advanced Synthesis, Biasca, were awarded to 10 students residing in Canton Ticino who are attending academic training in the chemical and pharmaceutical sectors. The scholarships have therefore been awarded to those carrying out an internship or attending the Federal Polytechnic or a Swiss university in one of the fields mentioned above.
The winners were selected following an assessment by the Helsinn Educational Scholarship Committee, which considered the candidates’ academic results and merits as well as their social-economic situation.
“Helsinn firmly believes in the importance of investing in talented young students. We are convinced that they represent the future not only for our company but also for the economy and territory of Ticino. Every year we encourage the most promising students through the Education Scholarships, which not only recognizes their academic achievements but above all, gives them the opportunity to cultivate their personal and professional development,” affirms Waldo Mossi, Local General Manager, Helsinn Advanced Synthesis.
“We are delighted to continue to invest in promising future local young talents and are pleased that this is the fourth year of the Helsinn Advanced Synthesis Education Scholarships. As chemical pharmaceutical company, we strongly believe that it is important to enhance the best up-and coming young students who come from our local territory, Canton Ticino, and are pleased to note their keen interest in science”.
Congratulations to the winners of the academic year 2017/2018:
Amoroso Benjamin, Cerboni Noemi, Danielli Saral, Ferrari Thomas, Garzoli Pietro, Huba Maria Kristina, Inguscio Elia, Meroni Alexandra, Pitton Melissa, Uterhofer Samuel.
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.
For more information:
Helsinn Group Media Contact
Group Head of Communication
Tel: +41 (0) 91 985 21 21